MX2009011836A - Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinaz olin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, en diferentes formas cristalinas, y composiciones farmaceuticas de las mismas. - Google Patents

Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinaz olin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, en diferentes formas cristalinas, y composiciones farmaceuticas de las mismas.

Info

Publication number
MX2009011836A
MX2009011836A MX2009011836A MX2009011836A MX2009011836A MX 2009011836 A MX2009011836 A MX 2009011836A MX 2009011836 A MX2009011836 A MX 2009011836A MX 2009011836 A MX2009011836 A MX 2009011836A MX 2009011836 A MX2009011836 A MX 2009011836A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
quinazolin
thiophen
dioxo
methylamino
Prior art date
Application number
MX2009011836A
Other languages
English (en)
Spanish (es)
Inventor
Anjali Pandey
Emma Sharp
Louisa Jane Quegan
Juan Wang
Matthew Nieder
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009011836A publication Critical patent/MX2009011836A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009011836A 2007-05-02 2008-05-02 Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinaz olin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, en diferentes formas cristalinas, y composiciones farmaceuticas de las mismas. MX2009011836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02
PCT/US2008/062584 WO2008137809A2 (en) 2007-05-02 2008-05-02 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
MX2009011836A true MX2009011836A (es) 2010-05-20

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011836A MX2009011836A (es) 2007-05-02 2008-05-02 Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinaz olin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, en diferentes formas cristalinas, y composiciones farmaceuticas de las mismas.

Country Status (18)

Country Link
US (1) US20090042916A1 (enExample)
EP (1) EP2076510A2 (enExample)
JP (1) JP2010526105A (enExample)
KR (1) KR20100020455A (enExample)
CN (1) CN101720324A (enExample)
AU (1) AU2008247457A1 (enExample)
BR (1) BRPI0810800A2 (enExample)
CA (1) CA2686221A1 (enExample)
CO (1) CO6241155A2 (enExample)
EA (1) EA200901474A1 (enExample)
EC (1) ECSP099779A (enExample)
GT (1) GT200900282A (enExample)
IL (1) IL201829A0 (enExample)
MA (1) MA31397B1 (enExample)
MX (1) MX2009011836A (enExample)
TN (1) TN2009000452A1 (enExample)
WO (1) WO2008137809A2 (enExample)
ZA (1) ZA200907493B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use
WO2019126557A1 (en) * 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4574100B2 (ja) * 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ， インコーポレイテッド 血小板ａｄｐレセプターインヒビター
ATE502928T1 (de) * 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
AU2004278030C1 (en) * 2003-10-03 2010-12-02 Portola Pharmaceuticals, Inc. 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
KR20100029746A (ko) * 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
KR20100020455A (ko) 2010-02-22
CO6241155A2 (es) 2011-01-20
TN2009000452A1 (en) 2011-03-31
MA31397B1 (fr) 2010-05-03
CN101720324A (zh) 2010-06-02
WO2008137809A3 (en) 2009-01-22
US20090042916A1 (en) 2009-02-12
ECSP099779A (es) 2010-01-29
ZA200907493B (en) 2010-07-28
CA2686221A1 (en) 2008-11-13
IL201829A0 (en) 2010-06-16
EP2076510A2 (en) 2009-07-08
BRPI0810800A2 (pt) 2014-10-29
AU2008247457A1 (en) 2008-11-13
GT200900282A (es) 2010-05-21
JP2010526105A (ja) 2010-07-29
WO2008137809A2 (en) 2008-11-13
EA200901474A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
WO2009155121A3 (en) Inhibitors of pi3 kinase
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
WO2008008539A3 (en) Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
WO2010108074A3 (en) Inhibitors of pi3 kinase
ATE517882T1 (de) Chinolinderivate
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201692214A1 (ru) Вещества, связывающие ядерные рецепторы
MX346186B (es) Inhibidores de proteina cinasas.
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2009120660A3 (en) Substituted pyridoxazines
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
ZA200806778B (en) N-Hydroxyacrylamide compounds
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal